p27 (phospho Ser178) Polyclonal Antibody

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-P (1:100-1:300), ELISA (1:5000). Not yet tested in other applications.

Liquid solution

PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.

Gel pack with blue ice.

CDKN1B encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The cyclin dependent kinase inhibitor 1B binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN6).

CDKN1B; KIP1; Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; p27Kip1

P46527